QTP-102

QTP-102 is a preclinical-stage vaccine candidate being developed by Quratis for the prevention of tuberculosis (TB). The program is supported by the RIGHT Foundation (Research Investment for Global Health Technology Foundation). As part of Quratis's infectious disease pipeline, QTP-102 represents a non-clinical effort to expand immunization options against Mycobacterium tuberculosis, complementing the company's more advanced clinical-stage TB vaccine candidates like QTP101. While specific details regarding the vaccine platform (such as whether it is a subunit, viral vector, or nucleic acid-based vaccine) are not publicly detailed in high-level pipeline summaries, the asset is positioned to address global health needs in TB prevention.